Form 8-K - Current report:
SEC Accession No. 0001213900-24-110303
Filing Date
2024-12-19
Accepted
2024-12-19 07:16:40
Documents
13
Period of Report
2024-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0225145-8k_oruka.htm   iXBRL 8-K 34189
  Complete submission text file 0001213900-24-110303.txt   208027

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE orka-20241217.xsd EX-101.SCH 3012
3 XBRL LABEL FILE orka-20241217_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE orka-20241217_pre.xml EX-101.PRE 22357
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0225145-8k_oruka_htm.xml XML 3678
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241560969
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)